Identification of a novel KIF13A-RET fusion in lung adenocarcinoma by next-generation sequencing

Autor: Hui Tian, Xuefei Zhang, Ge Sun, Zhibo Miao, Weifeng Wang, Changhong Liu, Xiaowei Dong, Desheng Lv, Ming Yao, Hui Chen, Kai Wang, Mo Li, Yanlin Li
Rok vydání: 2018
Předmět:
0301 basic medicine
Pulmonary and Respiratory Medicine
congenital
hereditary
and neonatal diseases and abnormalities
endocrine system
Cancer Research
Lung Neoplasms
Oncogene Proteins
Fusion
endocrine system diseases
Cabozantinib
medicine.medical_treatment
Kinesins
Adenocarcinoma of Lung
Vandetanib
Bioinformatics
Translocation
Genetic
Targeted therapy
03 medical and health sciences
Exon
chemistry.chemical_compound
0302 clinical medicine
Asian People
medicine
ROS1
Humans
Molecular Targeted Therapy
Lung cancer
Protein Kinase Inhibitors
neoplasms
Neoplasm Staging
business.industry
High-Throughput Nucleotide Sequencing
Middle Aged
medicine.disease
Treatment Outcome
030104 developmental biology
Oncology
Protein kinase domain
chemistry
030220 oncology & carcinogenesis
Cancer research
Adenocarcinoma
Female
business
medicine.drug
Zdroj: Lung Cancer. 118:27-29
ISSN: 0169-5002
DOI: 10.1016/j.lungcan.2017.08.019
Popis: Objectives RET fusions have been reported in 1–2% of lung adenocarcinomas, and represent an actionable target. Patients whose tumors possess RET fusion are associated with clinical benefit from the treatment with multi-kinase inhibitors such as cabozantinib and vandetanib. Further molecular screening for RET fusions is warranted. Novel KIF13A-RET fusion containing an intact RET kinase domain involving exons 1–18 of KIF13A and exons 12–20 of RET was identified in a lung cancer specimen from an 74-year-old Asian never smoker by next-generation sequencing (NGS) during clinical care. The patient was negative for EGFR, ALK, ROS1 and other putative driver alterations. Fusion analysis is consistent with other described RET fusions and is predicted to result in aberrant constitutive activation caused by dimerization and sensitivity to RET-directed therapies. We describe a novel RET-fusion with molecular characteristics consistent with RET-driven non-small cell lung cancer. Our case expands the spectrum of RET fusion partners and supports broad molecular profiling in non-small cell lung cancer optimizing patient therapeutic options. The new RET fusion has immediate clinical implications for cancer patients.
Databáze: OpenAIRE
Externí odkaz: